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ARTICLE
Epigenetic Allele Silencing Unveils Recessive RYR1 Mutations
in Core Myopathies
Haiyan Zhou, Martin Brockington, Heinz Jungbluth, David Monk, Philip Stanier, Caroline A. Sewry,
Gudrun E. Moore, and Francesco Muntoni
Epigenetic regulation of gene expression is a source of genetic variation, which canmimic recessive mutations by creating
transcriptional haploinsufﬁciency. Germline epimutations and genomic imprinting are typical examples, although their
existence can be difﬁcult to reveal. Genomic imprinting can be tissue speciﬁc, with biallelic expression in some tissues
andmonoallelic expression in others or with polymorphic expression in the general population.Mutations in the skeletal-
muscle ryanodine-receptor gene (RYR1) are associated with malignant hyperthermia susceptibility and the congenital
myopathies central core disease and multiminicore disease. RYR1 has never been thought to be affected by epigenetic
regulation. However, during the RYR1-mutation analysis of a cohort of patients with recessive core myopathies, we
discovered that 6 (55%) of 11 patients had monoallelic RYR1 transcription in skeletal muscle, despite being heterozygous
at the genomic level. In families for which parental DNA was available, segregation studies showed that the nonexpressed
allele was maternally inherited. Transcription analysis in patients’ ﬁbroblasts and lymphoblastoid cell lines indicated
biallelic expression, which suggests tissue-speciﬁc silencing. Transcription analysis of normal human fetal tissues showed
that RYR1 was monoallelically expressed in skeletal and smooth muscles, brain, and eye in 10% of cases. In contrast, 25
normal adult human skeletal-muscle samples displayed only biallelic expression. Finally, the administration of the DNA
methyltransferase inhibitor 5-aza-deoxycytidine to cultured patient skeletal-muscle myoblasts reactivated the transcrip-
tion of the silenced allele, which suggests hypermethylation as a mechanism for RYR1 silencing. Our data indicate that
RYR1 undergoes polymorphic, tissue-speciﬁc, and developmentally regulated allele silencing and that this unveils recessive
mutations in patients with core myopathies. Furthermore, our data suggest that imprinting is a likely mechanism for
this phenomenon and that similar mechanisms could play a role in human phenotypic heterogeneity.
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Mutations in the coding sequence of genes have a well-
established role in the determination of phenotypic di-
versity and pathological conditions. In the past few years,
modiﬁcation in the DNA or chromatin structure due to
DNA methylation, the covalent modiﬁcation of cytosine,
and posttranslational modiﬁcation of histones such as
methylation, acetylation, phosporylation, andsumoylation
have been recognized as contributing to allele expres-
sion.1 Collectively, these mechanisms of gene regulation
are termed “epigenetic modiﬁcations” and include ge-
nomic imprinting, germline epimutation, and epigenetic
polymorphism secondary to ormediated by aberrant DNA
methylation and/or histone modiﬁcation.2–4
Genomic imprinting describes a parent-of-origin–depen-
dent epigenetic mechanism through which a subset of
genes is expressed from only one allele. For some im-
printed genes, one parental allele is totally silenced in all
or virtually all tissues.2,5 Most imprinted genes contain
differentially methylated regions (DMRs), which function
as imprinting control regions (ICRs), in which the mater-
nal and paternal alleles are differentially methylated. De-
letions of these ICRs can disturb the transcription of im-
printed genes, which can be located 11 million bp away.6,7
For a restricted number of genes, the imprinting is tissue
speciﬁc, which leads to biallelic expression in some tissues
and monoallelic expression in others.8 The allele-speciﬁc
loss of expression can also be polymorphic; that is, it can
vary between individuals. Examples of genes that are poly-
morphically imprinted include the Wilms tumor 1 gene
(WT1) and serotonin 2A receptor genes.9,10
Some epigenetic changes can be transmitted unchanged
through the germline (termed “epigenetic inheritance”).
Evidence that this mechanism occurs in humans was re-
cently provided by Suter et al.,3 by the identiﬁcation of
individuals in whom one allele of the gene encoding the
DNA mismatch-repair protein MLH1 was epigenetically si-
lenced throughout the soma (implying a germline event).3
These individuals are affected by hereditary nonpolypo-
sis colorectal cancer but do not have any identiﬁable mu-
tation in MLH1, even though it is silenced, which dem-
onstrates that an epimutation can phenocopy a genetic
disease.
Genomic imprinting, on the other hand, is reversible
through successive generations. The inherited imprints are
erased in primordial germ cells, and, within each genera-
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Table 1. PCR Primers and Restriction Enzymes Used for Genotyping SNPs
SNPa
dbSNP
Allele
Heterozygosity
(%)
Genomic DNA cDNA
Restriction
Enzyme
Primer Fragment
Size
(bp)
Primer Fragment
Size
(bp)Forward Reverse Forward Reverse
rs2229146 C/T 41.8 GTGGAGGGGGTAGAATGGAC TTTTCTGCCAGTTGTTCTGC 294 CACAAAGTGCCCAGACCTATG TAACCGCGTAGCCATTCATCT 285 CfoI
rs2071089 A/G 41.4 GGGTGCAGTAGCATTCCAAC ATCAGCTCTGGAATCGGAGA 282 TCCCCACATGAACAGGAGATT TCAGGGCCTGACTTCATCACT 293 PvuII
rs11083462 C/T 48.6 CCCCACACCATGTCTTCTCT ACCGTCCCCAATCTCAATCT 211 GCAGTCACCACAGGCGAGATG ATGGCAAAGAACCTCAGAGAG 368 MboI
rs2228069b A/G 48.3 GCCCGCAGGTATATGATGAG TCGATGTTGTAGCCGTAGCC 296 TCTGGGGAGACGCTCAAGACT CTTCATCCAGCAGGCGGTAGG 316 …
rs2229139b A/G 48.2 ACCCTTGATTTCTGGCCTCT GTATGCCTGAAGGGCAACAT 250 CAGGAGGACGCAACAGGAGAG AGCAGGGGAAATGGTCAGACA 297 …
a Cluster ID of SNP.
b No restriction enzyme was available.
tion, new imprints are reset during gametogenesis and are
maintained throughout development.11
Core myopathies, including central core disease (CCD
[MIM 117000]) and multiminicore disease (MMD [MIM
255320]), are characterized by corelike structures in pa-
tient skeletal-muscle biopsy samples, as a result of the lack
of oxidative enzyme activity, and have been associated
with mutations in the skeletal-muscle ryanodine receptor
(RYR1 gene [MIM 180901; GenBank accession number
NP_000531]) on chromosome 19q13.1.12–14 In addition,ma-
lignant hyperthermia susceptibility (MHS [MIM 145600]),
a pharmacogenetic predisposition to develop a severe re-
action after the administration of general anesthetics, is
also due to mutations in the RYR1 gene. Most patients with
CCD and MHS carry dominant RYR1 mutations, whereas
MMD is recessively inherited.15 Most RYR1 mutations in
CCD andMHS induce depletion of sarcoplasmic reticulum
calcium stores, with resultant increase in cytosolic calcium
levels (“leaky channels”), whereas recessive MMD muta-
tions appear to affect RyR1 function in a more subtle
way.12,16
During the mutation analysis of a cohort of patients
with recessive core myopathies, we discovered that, in a
proportion of them, RYR1 was transcribed from only one
allele (i.e., monoallelic expression) in skeletal muscle. The
transcribed allele in skeletal muscle carried a recessivemu-
tation. Surprisingly, transcription analysis of patient ﬁ-
broblasts and lymphoblastoid cell lines indicated bial-
lelic transcription, suggesting tissue-speciﬁc allele silenc-
ing. Transcription studies in normal human fetal tissues
revealed a monoallelic transcription pattern for RYR1 in
a proportion (10%) of fetuses, whereas this phenomenon
was not found in 25 unaffected adult skeletal-muscle sam-
ples. These results suggest that recessive RYR1 mutations
in a proportion of patients with core myopathies can be
unveiled by lack of expression of the other, apparently
wild-type, allele. Various lines of experimental evidence
suggest that this is due to genomic imprinting in these
patients, although other epigenetic modiﬁcation of allele
expression cannot be deﬁnitively excluded.
Material and Methods
Mutation Analysis
Total RNA was extracted from frozen skeletal-muscle biopsy sam-
ples and from myogenic differentiation antigen (MyoD)–trans-
formed skin ﬁbroblasts, with use of the RNeasy mini kit (QIA-
GEN). Total RNA (1–2 mg) was reversely transcribed using Super-
Script III ﬁrst-strand synthesis system kit (Invitrogen). The cDNA
was subsequently used for the following ampliﬁcation reactions:
27 overlapping fragments were ampliﬁed, with a range of 400–
1,000 bp, covering the entire 15-kb coding sequence of the RYR1
gene (primer sequences available on request). PCR ampliﬁcation
of exons 4, 12, 45, 57, 91, and 96 of RYR1 were performed on
genomic DNA with exon-speciﬁc primers. Platinum pfxDNA poly-
merase (Invitrogen) was used in the ampliﬁcation. A touchdown
program was used for all PCR conditions, with use of GeneAmp
PCR System 9700 (Applied Biosystem [ABI]). Brieﬂy, the annealing
temperature started at 65C and decreased, in steps of 0.5C per
cycle, to 55C. After 20 cycles, another 15 cycles were performed
with an annealing temperature of 55C. All PCR products were
gel-puriﬁed by using the QIAquick gel-puriﬁcation kit (QIAGEN)
and were directly sequenced, in forward and reverse directions,
with use of an ABI 3730XL automated sequencer.
Haplotype Study
DNA samples extracted from peripheral blood were genotyped
for ﬁve microsatellite markers (D19S897, D19S421, RYR1 intra-
genic marker, D19S422, and D19S417) spanning the RYR1 locus.
PCR conditions were the same as those for mutational analysis.
Ampliﬁed products were run on an ABI PRISM 3730 DNA se-
quencer machine, followed by analysis of the results with use of
GeneMapper version 3.7 software.
SNP Analysis of Human Fetal and Adult Control Tissues
Five SNPs (rs2229146, rs2071089, rs11083462, rs2228069, and
rs2229139) in the RYR1 gene were used to assess heterozygosity.
Primer sets and speciﬁc restriction enzymes of SNPs are listed in
table 1. The PCR and ampliﬁcation conditions are described in
the “Mutation Analysis” section.
Cell Cultures
Myoblast and skin ﬁbroblast cell lines were established from pa-
tient skeletal-muscle and skin biopsy samples. Myoblast cultures
were puriﬁed using a commercially available system (Miltenyi Bio-
tec) and primary antibody anti-CD56.17 Myoblast cell cultureswere
maintained in skeletal-muscle growthmedium supplementedwith
5% fetal calf serum (FCS), 50 mg/ml fetuin, 1 ng/ml basic ﬁbroblast
growth factor, 10 ng/ml epidermal growth factor, 10mg/ml insulin,
and 0.4 mg/ml dexamethasone (PromoCell). The muscle-cell phe-
notype was conﬁrmed immunohistochemically in each culture,
with use of antibodies to the muscle-speciﬁc protein desmin.
Skin ﬁbroblasts were cultured in Dulbecco’s modiﬁed Eagleme-
dium (DMEM) supplemented with 10% fetal bovine serum. To
force myogenesis, ﬁbroblasts were transfected with a MyoD-en-
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Figure 1. Monoallelic expression of the RYR1 gene in six patients with core myopathies. Chromatograms for the sequencing of skeletal-
muscle cDNA, genomic DNA (gDNA), and parental genomic DNA from six patients (P1–P6) with RYR1 mutations. The details of six
mutations, including nucleotide changes in cDNA sequences and amino acid substitutions, are presented at the top of individual patient
lanes. In all six patients, there was monoallelic expression of the mutations in skeletal-muscle cDNA, despite the fact that all patients
clearly were heterozygous at the genomic DNA level. Allele-transmission studies indicate that, in four cases (P1, P2, P3, and P5), the
only allele transcribed was the paternal one, which carried the mutation, whereas the maternal allele was silenced at the transcriptional
level. An asterisk (*) indicates the position of mutation; a dash indicates that there was no sample available. The nucleotide sequences
are shown above the chromatogram peaks. For P4, the nucleotide change was on the last nucleotide residue in exon 57; therefore, the
sequences after the mutation differed between DNA and cDNA.
coding adenovirus (Crucell). After incubation for 3 h, cells were
washed with DMEM and then were allowed to differentiate into
multinucleated myotubes by culturing in differentiationmedium
(DMEM supplemented with 2% horse serum) for 5–7 d.
Lymphoblastoid cell lines were established from patient pe-
ripheral-blood leukocytes andwere transformedwith Epstein Barr
virus (EBV) by Health Protection Agency of European Collection
of Cell Cultures. Cells were cultured in RPMI-1640 supplemented
with 20% FCS.
5-Aza-Deoxycytidine (5-azaC) and Trichostatin A (TSA)
Treatments
Puriﬁed myocytes were planted at a density of cells/dish54# 10
in four dishes containing skeletal-muscle growth medium. After
24 h, 10 mM 5-azaC was added to dishes 1 and 2. Growthmedium
with freshly added 5-azaC was changed on day 3. In the mean-
time, 50 nM TSA was added to dish 2 (in the presence of 5-azaC)
and dish 3 on day 3.18 At the doses employed (50 nM), TSA did
not induce apoptosis or signs of cell toxicity.19 Dish 4 was used
as an untreated control. After 24 h, cells were collected, and total
RNA was extracted, as described above, from all four dishes. Re-
verse transcription was performed, following the manufacturer’s
instructions. PCR was performed using the touchdown program
described in the ”Mutation Analysis” section. The primers used
to amplify an 824-bp cDNA product were 5′-TCCAAGGAGAAGC-
TGGATGTG-3′ (forward) and 5′-TGCTTGTCCAGGAGGGAGATG-
3′ (reverse). To exclude genomic DNA product contamination, the
forward primer spanned the junction of exons 10 and 11, whereas
the reverse primer was in exon 17. The same primers were used
to amplify cDNA from skeletal-muscle tissue. After agarose-gel
puriﬁcation, PCR products were sequenced directly.
Bisulﬁte-Modiﬁed Genomic Sequencing
Skeletal-muscle DNA samples (2 mg) were treated with bisulﬁte
by using EZ DNAMethylation-gold Kit (Zymo Research) andwere
diluted into 10-ml M-elution buffer. For the following PCR, 1 ml
was used. Bisulﬁte-modiﬁed skeletal-muscle DNA was ampliﬁed
with Hotstart Taq DNA polymerase (Qiagen). A touchdown pro-
gram was used to amplify the products. PCR conditions were as
follows: at 95C for 15 min; followed by 20 cycles performed at
94C for 30 s; with an annealing temperature, starting at 65C
and decreasing in steps of 0.5C per cycle until 55C, for 30 s;
and an extension at 72C for 1 min. After 20 cycles, another 20
cycles were performed as follows: denaturing at 94C for 30 s,
annealing at 55C for 30 s, and extension at 72C for 1 min,
followed by a ﬁnal extension at 72C for 10 min. The primer sets
used to amplify three CpG islands were 5′-TTGTGAAATGGGAGA-
ATGATGGTA-3′ and 5′-AATCTCAAAAACCACCAACAAACC-3′ for
CpG I, 5′-GAGATGGGGGTTTTATTATGTATATTG-3′ and 5′-AAA-
AATCAAAATCCCTACCTTAACT-3′ for CpG II, and 5′-TTTGTGGT-
TTGTAGTATTTGTGGTA-3′ and 5′-CCAAAATTCTCTACCCCTTC-
AAAC-3′ for CpG III. Ampliﬁed fragments were gel-puriﬁed and
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Figure 2. Pedigrees of two affected families, Fp1 and Fp3. Black-
ened symbols denote symptomatic patients with core myopathy;
unblackened symbols indicate asymptomatic individuals. Haplo-
types are derived from DNA satellite markers, listed on the left.
Arrows indicate the probands. The deceased individual is marked
with a diagonal bar. The maternal haplotype in Fp3 is reconstructed.
Individuals II:1 and II:2 in Fp1 and II:1, II:2, and II:4 in Fp3 are
affected by the core myopathy, whereas the parents are completely
asymptomatic.
Figure 3. Allelic-expression study of an unaffected mother. Chro-
matograms for the sequencing of SNPs rs2228069 and rs11083462
show that both SNPs are heterozygous in patient P2’s maternal
genomic DNA, and the corresponding skeletal-muscle cDNA shows
consistent biallelic transcription.
were sequenced directly. The puriﬁed products were cloned us-
ing the TOPO TA cloning system (Invitrogen). Individual clones
were isolated using a Qiaprep minispin kit (Qiagen) and were se-
quenced with sense and antisense M13 primers by using standard
ABI sequencing technology to determine the methylation status
of the CpG dinucleotides. Only DNA strands that were 195%
converted were used for analysis.
Results
Identiﬁcation of Monoallelic RYR1 Expression in Patients
with Core Myopathies
Investigation of the RYR1 gene in a cohort of patientswith
clinical and pathological features evocative of recessive
core myopathies revealed an unexpected phenomenon.
Sequencing of skeletal-muscle cDNA showed that 6 (55%)
of 11 patients had apparent homozygous RYR1 missense
mutations, yet subsequent analysis unequivocally demon-
strated that all patients were heterozygous at the genomic
DNA level (ﬁg. 1); further studies showed that this appar-
ent homozygosity for the mutant allele was the result of
silencing of the other allele (see below). None of the pa-
tients were from consanguineous families; four were spo-
radic cases, and two (P1 and P3) were familial cases. RT-
PCR was repeated by using different combinations of
primers, and no additional bands were seen when prod-
ucts were run on the agarose gel. The mutations identiﬁed
in these six patients are presented in ﬁgure 1. Recessive
inheritance was suggested by linkage studies in two fam-
ilies with multiple affected individuals and by the clinical
analysis of their unaffected parents (ﬁg. 2). The mutations
found in these patients are likely to be pathogenic, since
they affect highly conserved residues across RyR isoforms
and species and are not present in a white control pop-
ulation (1200 chromosomes). In addition, three of these
patients were informative for other coding-region SNPs lo-
cated at variable distances from the mutated exons, which
also showed monoallelic expression (data not shown).
Promoter and 3′ UTR mutations were excluded, in all six
patients with core myopathies, by direct sequencing of
the RYR1 promoter and 3′ UTR regions.20
Recessive mutations were identiﬁed in the remaining 5
(45%) of the 11 patients with coremyopathies, all of whom
showed biallelic RYR1 expression in skeletal muscle. These
were three homozygous missense mutations, which in-
cluded two mutations identiﬁed in consanguineous fam-
ilies and one homozygous change in a family without ap-
parent consanguineous background, as well as two pairs
of compound heterozygous mutations, which included
three missense mutations and one splice-site mutation (H.
Zhou, H. Jungbluth, E. Bertini, K. Bushby, V. Straub, H. Ro-
per, M. R. Rose, M. Brockington, L. Feng, C. R. Mu¨ller, A.
Manzur, S. Robb, S. Messina, S. Brown, S. Treves, C. A.
Sewry, and F. Muntoni, unpublished data).
Parent-of-Origin–Dependent Monoallelic RYR1 Expression
In the four (of six) patients for whom parental genomic
DNA samples were available, we could demonstrate that
the mutated allele was invariably inherited from the clin-
ically unaffected father (ﬁg. 1). In one family (P2), we were
able to study the skeletal muscle from the clinically un-
affected mother, who had transmitted the untranscribed
allele; analysis of two SNPs in both genomic DNA and
skeletal-muscle cDNA showed that both her alleles were
transcribed (ﬁg. 3). These results clearly showed allele-spe-
ciﬁc silencing inherited from the parent(s), which raises
the possibility of genomic imprinting.
Tissue-Speciﬁc RYR1 Silencing in Patients with Core
Myopathies
Since the RYR1 gene is also transcribed in tissues other
than skeletal muscle—including lymphocytes21 and, to a
lesser degree, ﬁbroblasts—we studied its transcription in
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Figure 4. Tissue-speciﬁc maternal-allele silencing of the RYR1
gene in patients with core myopathy. A, Chromatograms of the
sequencing of cDNA derived from skeletal muscle, skin ﬁbroblast,
and lymphoblastoid cell lines. In contrast to the monoallelic ex-
pression in skeletal muscle, the cDNA from P1’s skin ﬁbroblast and
MyoD adenovirus–transfected skin ﬁbroblast and P6’s lymphoblas-
toid cell lines show biallelic expression. An asterisk (*) indicates
the mutation position. B, Increased expression of RYR1 after forced
myogenesis of skin ﬁbroblast–derived myoblasts. RT-PCR shows
weak expression of RYR1 in skin ﬁbroblasts. The level of RYR1
transcription is noticeably higher after the MyoD transfection, be-
cause of the induced myogenicity.
skin ﬁbroblasts and EBV-immortalized lymphoblastoid cell
lines from two (P1 and P6) of the six patients with mono-
allelic skeletal-muscle transcription. The results showed
biallelic expression in ﬁbroblasts from patient P1 and lym-
phoblastoid cell lines from patient P6 (ﬁg. 4A), which sug-
gests that the monoallelic expression is tissue speciﬁc.
To assess whether the monoallelic expression at the
RYR1 locus could be induced by forcing myogenesis of
patients’ ﬁbroblasts, we transfected the ﬁbroblasts from
patient P1 with a MyoD-adenoviral vector.22 Transcrip-
tional analysis of MyoD-transformed ﬁbroblasts from
this patient with skeletal-muscle monoallelic transcrip-
tion showed that RYR1 transcription retained the biallelic
pattern (ﬁg. 4A), irrespective of the expected up-regulation
of RYR1 transcription that followed the MyoD transfec-
tion (ﬁg. 4B). The expression of desmin and myosin con-
ﬁrmed the myogenicity of these cells (not shown).
To rule out the unlikely possibility of chain-terminating
mutations giving rise to a tissue-speciﬁc nonsense-medi-
ated RNA decay, we sequenced the entire cDNA derived
from MyoD-transfected ﬁbroblasts from individual P1 of
family Fp1, since we had conﬁrmed biallelic expression in
his ﬁbroblasts. No additional mutation was identiﬁed in
this patient.
RYR1 Transcription in Human Fetal Tissues
To better understand the mechanism leading to RYR1
monoallelic expression, we investigated multiple tissues
from unaffected human fetuses. Informative fetuses were
ﬁrst identiﬁed by studying ﬁve highly polymorphic SNPs
located in the coding sequence of RYR1 (table 1). Of the
57 fetuses, 39 were heterozygous for at least one SNP in
genomic DNA; these fetuses were further characterized at
the transcription level. In 4 (∼10%) of these 39 fetuses,
monoallelic expression was detected in skeletal muscle as
well as in intestine, eye, brain, and spinal cord, whereas,
in other tissue samples, including lung, placenta, heart,
spleen, adrenal, and pancreas, the expression was biallelic
(ﬁg. 5). This pattern of expression was conﬁrmed by direct
sequencing and restriction-enzymedigestion.ParentalDNA
samples were not available for conﬁrmation of the origin
of the silenced RYR1 allele in these fetuses. The frequency
of RYR1 monoallelic expression (10%) in unaffected fe-
tuses was lower than the 55% found in patients with re-
cessive core myopathies, most likely reﬂecting the ascer-
tainment bias of the patient group. These results, there-
fore, strongly suggest that RYR1 monoallelic expression is
polymorphic and follows a tissue-speciﬁc pattern during
human fetal development.
RYR1 Transcription in Control Adult Human Muscle
To determine whether some RYR1 alleles are silenced in
the general adult population, we obtained 39 adult skel-
etal-muscle biopsy samples and analyzed the ﬁve SNPs
previously used. We identiﬁed 25 heterozygous individ-
uals. The RYR1 gene was found to be biallelically expressed
in all individuals (data not shown). The data from the
general adult population, together with the fetal studies,
suggest that the epigenetic RYR1 silencing is developmen-
tally regulated.
Methylation Study of RYR1 Monoallelic Expression
Patient P2 carries a paternally derived missense mutation
(c.1205TrC), which affects the only allele expressed in her
skeletal-muscle cDNA. Transcription studies of cultured
primary myoblasts from the patient showed a pattern of
monoallelic expression identical to that in her skeletalmus-
cle (ﬁg. 6A). Since epigenetic modiﬁcation of transcription
is due mainly to differential DNA methylation or histone
deacetylation, we applied the DNA methyltransferase in-
hibitor 5-azaC and the histone deacetylase inhibitor TSA
to cultured myoblasts.18 Administration of 5-azaC reacti-
vated transcription of the silenced maternal allele when
applied alone or in combination with TSA, whereas treat-
ment with TSA alone did not show reactivation of the
silenced maternal allele (ﬁg. 6A), which suggests that DNA
methylation plays the major role in the silencing of the
maternal RYR1 allele.
Methylation of CpG Islands in the 5′ Region of RYR1 Gene
To seek the DMR associated with RYR1 silencing, we stud-
ied the methylation status of the 5′ region of the RYR1
gene in the patients with monoallelic expression. This re-
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Figure 5. Monoallelic expression of the human RYR1 gene in unaffected fetuses. A, Monoallelic expression of the human RYR1 gene,
which is tissue speciﬁc. Highly polymorphic SNPs were studied in both genomic DNA and cDNA from human fetuses. In four heterozygous
fetuses, cDNA from limb (skeletal muscle), brain, spinal cord, eye, and intestine show monoallelic expression, whereas lung, placenta,
heart, spleen, adrenal tissue, and pancreas cDNA show biallelic transcription. Dashes indicate that samples were not available. B,
Sequencing chromatograms of SNP analysis. An asterisk (*) indicates the position of the SNP.
gion contains the promoter, exon 1, intron 1, and exon
2 (nucleotides 2730 to 7035). The presence of three
CpG islands was identiﬁed by using Methprimer software
(ﬁg. 6B). CpG I contains 17 CpG dinucleotides (nucleo-
tides 177 to 61), which occupy a small part of the
promoter region, the whole 5′-UTR, and the entire exon
1. CpG II is located in intron 1 (nucleotides 4815–4985)
and contains 10 CpG dinucleotides. CpG III includes the
entire exon 2 (nucleotides 6890–6998) and contains 13
CpG dinucleotides. We used bisulﬁte sequencing to screen
genomic DNA isolated from the skeletal muscle of ﬁve
patients with monoallelic RYR1 expression and eight con-
trol skeletal-muscle samples. No differential methylation
was found in CpG I, either in the patient group or in con-
trols (ﬁg. 6C). Hypermethylation was identiﬁed in CpG II
and CpG III, although there was no difference between
the patient group and controls (ﬁg. 6C). This suggests that
methylation of CpG islands I, II, and III is not responsible
for the monoallelic expression of the RYR1 gene.
Ryr1 Transcription in Mouse
To see whether expression of the Ryr1 gene (GenBank ac-
cession number NP_033135) is monoallelic in mouse, we
sequenced the cDNA fromC57BL/6 and CAST/Eimice and
identiﬁed an A/G SNP between the two species. Analysis
of this SNP in reciprocal F1 crosses clearly showed that
Ryr1 expression was biallelic in whole E16.5 embryos as
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Figure 6. Mechanism of RYR1 monoallelic expression. A, Analysis of the silenced allele in cultured skeletal myocytes from patient P2
after inhibition of DNA methyltransferase (by 5-azaC) and histone deacetylase (by TSA) activity. Chromatograms of the sequenced RT-
PCR products spanning mutation c.1205TrC show that the cultured primary skeletal myoblasts have the same monoallelic expression
as do skeletal-muscle tissue. The mutant C peak (arrow) indicates the paternal allele, and the T peak indicates the maternal allele.
Only 5-azaC signiﬁcantly increased the expression of the silenced maternal allele, either alone or in combination with TSA. TSA had
no effect on its own. B, Schematic representation of the 5′ region of the human RYR1 gene. Exons are indicated by blackened boxes.
The bent arrow indicates transcription start site, and CpG islands are as indicated by numbered position. All three CpG islands were
analyzed by bisulﬁte sequencing. C, Cloning and sequencing of bisulﬁte PCR products from skeletal-muscle DNA of monoallelic patients
and biallelic controls. Complete absence of methylation and hypermethylation of CpG dinucleotides is indicated as unblackened and
blackened dots, respectively. After the quantiﬁcation of methylation by cloning and sequencing, no difference in the methylation status
between patient and controls was found in the three CpG islands.
well as in brain and skeletal-muscle cDNA from newborn
animals (data not shown). These data indicate that the
Rry1 gene is not expressed monoallelically in mouse.
Discussion
In this study, we describe—to our knowledge, for the ﬁrst
time—that RYR1, encoding the skeletal-muscle ryanodine
receptor, undergoes epigenetic allele silencing during nor-
mal human development in a tissue-speciﬁc fashion.More-
over, we were able to demonstrate that, of the patients
with core myopathies we studied—a group of patients
with clinicopathological features suggestive of recessive
RYR1 involvement—55% had monoallelic expression in
skeletal muscle but not in other tissues. The monoallelic
expression unveiled the presence of the apparently reces-
sive mutation. The unmasking of recessive mutations in
patients with core myopathies is a phenomenon similar
to the discovery of isodisomy in cystic ﬁbrosis, in which
patients inherit a recessive allele from one parent only.23
Various lines of evidence suggest that the monoallelic
RYR1 expression observed in the skeletal muscle of our
patients is the result of epigenetic modiﬁcation. We ex-
cluded changes in the nucleotide sequence of RYR1 in
these patients by studying not only the coding region but
also the promoter and the 3′ UTR regions. We have dem-
onstrated, by studying intragenic SNPs, that these patients
do not carry large-scale deletions. We have also clearly
demonstrated biallelic expression in several tissues other
than skeletal muscle. This makes it very unlikely that
chain-terminating mutations could be present on the si-
lenced allele, a possibility that was further excluded by
direct sequencing of the entire cDNA from biallelic ﬁbro-
blasts of a patient with monoallelic skeletal-muscle tran-
scription. Although a tissue-speciﬁc splicing defect has
been recently reported in one patient with core myopa-
thy,24 our patients’ RT-PCR studies failed to identify any
additional products, despite study of different combina-
tions of primers, which suggests that a mutation affecting
tissue-speciﬁc splicing is very unlikely. Finally, the resto-
ration of biallelic expression after treatment with the
DNA methyltransferase inhibitor 5-azaC in one patient’s
primary myoblasts provides evidence toward epigenetic
modiﬁcation of RYR1 transcription in these patients with
monoallelic expression.
Which epigenetic mechanisms could be responsible for
the observed monoallelic expression? The phenomenon
ofmonoallelic expression shares several characteristicswith
epimutation, epigenetic polymorphism, and imprinting.
The role of germline epimutations is increasingly being
recognized in cancer, since the demonstration of epimu-
tations of the DNA mismatch-repair gene MLH1 in two
individuals with multiple primary tumors.3 In addition,
variations in gene expression secondary to epigenetic poly-
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morphisms are likely to play a major role in human var-
iability, as suggested by the surprising ﬁnding that allelic
imbalance affected 6 of 13 genes studied by Yan et al.,25
and ratios for those alleles differentially expressed varied
from 1.3:1.0 to 4.3:1.0. These studies were extended by
Lo et al.,26 who found that 150% of 602 studied genes
showed preferential expression of one allele in at least one
individual, and ∼55% of those showed greater than four-
fold difference between the two alleles; most of these
genes were distributed throughout the genome, in areas
not located in known imprinting domains. Several indirect
lines of evidence suggest that the epigenetic mechanism
leading to RYR1 monoallelic expression in a proportion
of cases is likely to be the result of genomic imprinting.
First, there is an association with the sex of the nontrans-
mitting parent, the mother in all informative cases stud-
ied. This phenomenon is a unique feature of genomic im-
printing. Second, the RYR1 monoallelic expression fol-
lowed a tissue-speciﬁc pattern, which would not be ex-
pected in other instances of epigenetic modiﬁcation. Third,
studies of unaffected fetuses conﬁrmed both the occur-
rence of silencing of RYR1 in an appreciable proportion
(10%) of cases and the tissue-speciﬁc nature of the si-
lencing. This, together with the biallelic expression found
in the unaffected adult control population, suggests a de-
velopmental pattern of allele silencing that is also a feature
of genomic imprinting.
Other genes have been reported in which tissue-speciﬁc
imprinting leads to monoallelic transcription that is lim-
ited to a subset of tissues.8 These include UBE3A, KCNQ1,
and GNAS1. The UBE3A gene, involved in Angelman syn-
drome, is imprinted in a subset of regions in the CNS,
with expression only from the maternal allele.27 Fetal-
tissue studies demonstrated that imprinted expression of
UBE3A is limited to the brain.28 The nearby ATP10C gene
is also preferentially maternally expressed in brain and
lymphoblasts.29,30 The KCNQ1 gene within the Beckwith-
Wiedemann syndrome–imprinted cluster on 11p15.5 is
expressed from only the maternal allele in most tissues
and also carries an associated antisense transcript (LIT1)
that is expressed only from the paternal allele31; KCNQ1
undergoes both tissue-speciﬁc and developmentally reg-
ulated imprinting, with maternal-speciﬁc expression oc-
curring during embryonic development and subsequent
(postnatal) loss of imprinting, which then results in bial-
lelic expression.32 The GNAS1 gene, a complex imprinted
locus on chromosome 20q13, encodesmultiple gene prod-
ucts through the use of alternative promoters and ﬁrst
exons that are differentially imprinted in a tissue-speciﬁc
manner.5,33,34
Polymorphic and tissue-speciﬁc imprinting has also been
described in humans. Examples include the Wilms tumor
1 gene (WT1), the serotonin 2A receptor (5-HT2A), and
the insulin-like growth factor II receptor gene (IGF2R).9,
10,35,36 However, the imprinting in all these examples has
no phenotypic effect, because of the lack of allele silencing
in affected tissues. In particular, KCNQ1, mutated in dif-
ferent forms of long–Q-T syndromes, is not imprinted in
the heart.32 Similarly WT1, mutated in some patients with
Wilms tumor and other complex conditions with renal
tumors, is imprinted in a proportion of patient ﬁbroblasts
but not in kidneys.9 Although the relevance of tissue-spe-
ciﬁc and polymorphic imprinting for human diseases has
been hypothesized in the past,8 a clear example of this
mechanism has never been documented before. We can-
not be absolutely certain that the monoallelic expression
we observed is the result of imprinting, as opposed to other
epigenetic modiﬁcation of gene expression; however, im-
printing seems the most plausible hypothesis.
The RYR1 gene, involved in congenital coremyopathies,
MMD, and MHS, had never been considered in terms of
imprinting or other epigenetic modiﬁcation. However, re-
duced penetrance of dominant RYR1 mutations is a well-
recognized phenomenon.37 Furthermore, marked “antici-
pation” of severity has also been reported in families with
rare dominant mutations, because severely affected chil-
dren have invariably inherited the phenotype fromamild-
ly affected father38 (F.M., personal observation).
The identiﬁcation of the RYR1monoallelic transcription
in our study was facilitated by the use of cDNA derived
from skeletal muscle, not the genomic DNA used in the
majority of previous reports.39 In the case of the recessive
RYR1 mutations in patients with silenced maternally in-
herited alleles, genomic DNA studies might indeed bemis-
leading. The fact that skeletal muscle is a target tissue for
RYR1 mutations has led to the clustering of individuals
with monoallelic transcription in our patient population.
Our studies of cultured myoblasts treated with the DNA
methyltransferase inhibitor 5-azaC suggest that themono-
allelic expression of RYR1 is associated with DNA meth-
ylation. Imprinted genes are usually associatedwith aCpG
island near or inside their promoters showing differential
methylation between two parental alleles. However, se-
quencing of the CpG islands located within the 5′ end of
the RYR1 gene—including the ﬁrst intron containing se-
quences involved in directing porcine skeletal-muscle tis-
sue-speciﬁc RYR1 transcription40—did not reveal differen-
tial methylation between patients and controls, which sug-
gests that the regulatory elements of RYR1 monoallelic
expression are localized outside this region. It is possible
that the RYR1 gene lies within a cluster of imprinted genes
regulated by a cis-acting element. Interestingly, both PEG3
and ZIM2, which are located on chromosome 19q13.4,
are also subject to maternal imprinting.41 However, the
physical distance between these genes and RYR1 (114Mb)
makes it unlikely that they belong to a single cluster.
Our ﬁnding that the mouse Ryr1 orthologue was not
imprinted was surprising andwill limit the value of animal
models in further investigation of the monoallelic RYR1-
expression mechanism. A large number of imprinted tran-
scriptional units show imprinting-status discordance be-
tween human and mouse, with most imprinted in mouse
but not in human.41 Nevertheless, another gene, L3MBTL,
is imprinted in human but not in the mouse orthologue.42
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In conclusion, we have identiﬁed the tissue-speciﬁc si-
lencing of the RYR1 that unveils paternally inherited re-
cessive mutations, a novel mechanism responsible for au-
tosomal recessive core myopathies. The polymorphic na-
ture of this phenomenon, together with its developmental
regulation in human, suggests that this is likely the result
of a genomic-imprinting mechanism mediated by DNA
methylation. It is possible that similar epigenetic modiﬁ-
cation of RYR1 expression accounts for both the reduced
penetrance and the “anticipation” of dominant RYR1mu-
tations. It is also likely that similar mechanisms play a role
in phenotypic heterogeneity of other known cell- or tis-
sue-speciﬁc human gene defects.
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